Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
MRK
HoldPremium GrowerAPPROVEMerck & Co., Inc. · Healthcare · United States · $366.0B · Avg Vol: $1.5B/d
This is the US line of Merck, which combines a dominant oncology franchise with a strong animal-health and vaccines business, generating large free cash flow supporting a growing dividend and buybacks, with strong momentum (M80). Nothing adverse is known on accounting, solvency or governance.
COMPANY DESCRIPTION
Merck & Co., Inc. is a leading global pharmaceutical company focused on the discovery, development, manufacturing, and marketing of innovative medicines, vaccines, and animal health products. With a robust R&D pipeline and blockbuster franchises like Keytruda in oncology, Merck maintains a formidable global market presence, addressing significant medical needs across various therapeutic areas.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 59.3B | 60.1B | 64.2B | 65.0B | 3.1% | 66.6B | 67.1B | 70.3B | 4.0% |
| EPS | 5.73 | 0.14 | 6.77 | 7.38 | 8.8% | 1.25 | 2.76 | 9.68 | 14.5% |
| Shares | 2.5B | 2.5B | 2.5B | 2.5B | -2.5% | 2.5B | — | — | — |
| Debt | 30.7B | 35.1B | 37.1B | 49.3B | 17.1% | 53.9B | — | — | — |
| Equity | 46.0B | 37.6B | 46.3B | 52.6B | 4.6% | — | — | — | — |
| Op CF | 19.1B | 13.0B | 21.5B | 16.5B | -4.8% | 20.0B | — | — | — |
| Inv CF | -5.0B | -14.1B | -7.7B | -13.7B | — | — | — | — | — |
| Fin CF | -9.1B | -4.8B | -7.0B | -1.9B | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of MRK are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| MRK | Merck & Co., Inc.(you) | $366.0B | 65 | Hold |
| AZN.L | AstraZeneca PLC | $251.3B | 68 | Buy |
| JNJ | Johnson & Johnson | $645.9B | 66 | Buy |
| NVS | Novartis AG | $292.3B | 75 | Buy |
| RO.SW | Roche Holding AG | $360.3B | 85 | Strong Buy |
| GILD | Gilead Sciences, Inc. | $180.6B | 74 | Buy |
| ABBV | AbbVie Inc. | $451.5B | 86 | Strong Buy |
| AMGN | Amgen Inc. | $233.8B | 86 | Strong Buy |
| LLY | Eli Lilly and Company | $1.0T | 77 | Buy |
| NVO | Novo Nordisk A/S | $201.6B | 89 | Strong Buy |
Peer medians: ROE 2.8% · P/E 24.3x · Gross margin 52.6%